What does 21 CFR 211.192 require? Production record review and investigations explained
By Savi C., Co-Founder · Published Nov 16, 2026
The regulation, sentence by sentence
Section 211.192 is four sentences long. Each one carries a separate obligation.
First: “All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.” The review covers every record for the batch, not only the manufacturing steps, and it measures the batch against your own approved procedures.
Second: “Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed.” Two kinds of event trigger an investigation, and shipping the batch does not end the obligation.
Third: “The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.” An investigation that looks only at the batch in front of you is incomplete.
Fourth: “A written record of the investigation shall be made and shall include the conclusions and followup.” The investigation is not finished until its conclusion and the actions taken are documented.
What each phrase asks of you
Phrase in 211.192
“All … production and control records, including those for packaging and labeling”
What it means in practice
Packaging records, labeling reconciliation and laboratory control records are reviewed, not only the manufacturing record
Phrase in 211.192
“to determine compliance with all established, approved written procedures”
What it means in practice
The yardstick is your master record, specifications and SOPs at the revision in effect for the batch
Phrase in 211.192
“before a batch is released or distributed”
What it means in practice
Review and approval precede release, so an open question blocks release until it is resolved
Phrase in 211.192
“Any unexplained discrepancy”
What it means in practice
Anything in the record that does not match what should have happened and has no documented explanation, including yield outside its limits
Phrase in 211.192
“whether or not the batch has already been distributed”
What it means in practice
A discrepancy found after shipment is still investigated, and may lead to further action on distributed product
Phrase in 211.192
“shall extend to other batches … and other drug products”
What it means in practice
The investigation asks what else could share the cause: other lots, shared equipment, shared materials
Phrase in 211.192
“shall include the conclusions and followup”
What it means in practice
The record states the cause found, the decision made and the corrective actions taken
How 211.192 connects to the rest of Part 211
Section 211.22(a) gives the quality control unit the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated. Section 211.100(b) requires any deviation from written production procedures to be recorded and justified. Section 211.188(b)(12) requires the batch record itself to include any investigation made under 211.192, and 211.165(f) requires products that fail their specifications to be rejected.
The investigations then feed the annual product review: 211.180(e)(2) requires that review to include investigations conducted under 211.192 for each product. FDA’s OOS guidance adds that batch rejection does not remove the need to investigate, because the investigation is what determines whether other batches or products are affected.
What a 211.192 investigation record should show
The first five items follow the written record FDA lists for a full-scale OOS investigation. The rest come from the regulation itself.
The investigation
- A clear statement of the reason for the investigation
- A summary of the aspects of the process that may have caused the problem
- The results of the documentation review, with the actual or probable cause assigned
- The results of a check for whether the problem has occurred before
- A description of the corrective actions taken
Scope and closure
- Which other batches and products were assessed, and why each was included or ruled out
- The impact on any batches already distributed
- The conclusion and the disposition decision it supports
- The follow-up, with owners and dates, and how its effectiveness will be checked
How Litewave fits
The first sentence of 211.192 is where review time goes: every entry in every record measured against approved procedures. Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from, so unexplained discrepancies surface before release rather than after. Litewave proposes, qualified people approve, and the approval required by 211.192 stays with your quality control unit.
Questions we get asked
Does 211.192 apply to batches that have already shipped?
Yes. The regulation says discrepancies and failures shall be thoroughly investigated whether or not the batch has already been distributed, and the investigation extends to other batches and products that may be associated with the problem.
Does every deviation need a 211.192 investigation?
Section 211.192 is triggered by unexplained discrepancies and by failures to meet specifications. Section 211.100(b) separately requires every deviation from written procedures to be recorded and justified. How deeply each deviation is investigated is set by your procedures and the risk involved, but an unexplained one falls under 211.192.
Does the regulation say how the record review must be done?
No. It requires the quality control unit to review and approve the records before release and does not prescribe a method. Whatever method you use, including software that screens entries, has to be documented, fit for its intended use and able to show the review was complete.
Sources
- 21 CFR 211.192, Production record review (eCFR)
- 21 CFR 211.22, Responsibilities of quality control unit (eCFR)
- 21 CFR 211.100, Written procedures; deviations (eCFR)
- 21 CFR 211.165, Testing and release for distribution (eCFR)
- 21 CFR 211.180, General requirements for records and reports (eCFR)
- 21 CFR 211.188, Batch production and control records (eCFR)
- FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (2022)
